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Abstract
Background: The patterns, performance characteristics, and yield of diagnostic tests ordered for the evaluation of
acute kidney injury (AKI) have not been rigorously evaluated.
Methods: We characterized the frequency of AKI diagnostic testing for urine, blood, radiology, and pathology
tests in all adult inpatients who were admitted with or developed AKI (N = 4903 patients with 5731 AKI episodes)
during a single calendar year. We assessed the frequency of abnormal test results overall and by AKI stage. We
manually reviewed electronic medical records to evaluate the diagnostic yield of selected urine, blood, and
radiology tests. Diagnostic yield of urine and blood tests was determined based on whether an abnormal test
affected AKI diagnosis or management, whereas diagnostic yield of radiology tests was based on whether an
abnormal test resulted in a procedural intervention. In sensitivity analyses we also evaluated appropriateness of
testing using prespecified criteria.
Results: Frequency of testing increased with higher AKI stage for nearly all diagnostic tests, whereas frequency
of detecting an abnormal result increased for some, but not all, tests. Frequency of detecting an abnormal result
was highly variable across tests, ranging from 0 % for anti-glomerular basement membrane testing to 71 % for
urine protein testing. Many of the tests evaluated had low diagnostic yield. In particular, selected urine and blood
tests were unlikely to impact AKI diagnosis or management, whereas radiology tests had greater clinical utility.
Conclusions: In patients with AKI, many of the diagnostic tests performed, even when positive or abnormal, may
have limited clinical utility.
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Background
Acute kidney injury (AKI) is an increasingly common
complication among hospitalized patients [1, 2], and is as-
sociated with increased mortality [3, 4], development of
chronic kidney disease [5, 6], and increased resource
utilization [7–9]. The optimal diagnostic approach to AKI
is not well established.
The traditional approach to the differential diagnosis of
AKI emphasizes three broad categories: pre-renal AKI,
which results from inadequate perfusion of the kidneys;
post-renal AKI, which results from obstruction to the flow
of urine; and intrinsic causes of AKI, which can be due to
injury or dysfunction of the glomeruli, other blood vessels,
tubules, or the interstitium. A large number of diagnostic
tests are available for the investigation of AKI. Determin-
ing which test to order in which patient with AKI should
be based on estimates of pre-test probability from the
clinical context and an appreciation of the diagnostic
performance characteristics of the various tests available.
Previous studies have examined the utility of some
AKI diagnostic tests in isolation, such renal ultrasonog-
raphy [10] and urine microscopy [11], but none have
comprehensively assessed the patterns and clinical utility
of a wide range of diagnostic tests in patients with AKI.
We performed this study to identify the frequency with
which various urine, blood, radiology, and pathology
tests are ordered in patients with AKI, and to assess
their diagnostic yield.
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We conducted a retrospective cohort study among inpa-
tients at Brigham and Women’s Hospital (BWH). All
protocols were approved by the BWH Institutional Re-
view Board.
Study cohort
BWH is a 777-bed tertiary care academic medical center
that provides care to an ethnically and socioeconomi-
cally diverse population. We analyzed all hospitalizations
of adult patients (age ≥ 18) who were admitted in 2010
and developed AKI. While participants could only be
considered to have a single episode of AKI per admission,
AKI during subsequent admissions was also included and
considered a separate AKI event. Thus, data were analyzed
at the AKI-event level. We excluded patients with end-
stage renal disease (ESRD) on maintenance hemo- or peri-
toneal dialysis and those who had undergone kidney
transplantation.
Data collection
We obtained data through the Research Patient Data
Registry, a central clinical data warehouse maintained by
Partners Healthcare System, of which BWH is a mem-
ber. We obtained information on patient demographics
(age, gender, race, comorbidities) and on patterns of
diagnostic testing for AKI, including urine, blood, and
radiology testing, as well as renal biopsy.
Definition and staging of AKI
We defined and staged AKI according to the serum cre-
atinine (SCr)-based criteria established by the Kidney
Disease Improving Global Outcomes (KDIGO) Work
Group [12]. Urine output data were not available. AKI
was defined as an increase in SCr ≥0.3 mg/dl over any
48 h time period during hospitalization or ≥50 % in-
crease in SCr over baseline known or presumed to have
occurred within 7 days. For patients meeting criteria for
AKI, we identified the AKI stage based on the ratio of
maximum SCr during hospitalization divided by the
baseline SCr, according to consensus criteria [12]. Base-
line SCr was defined as the mean of all available out-
patient SCr measurements obtained 7 to 365 days prior
to admission, a validated approach described previously
[13]. If no outpatient SCr values were available, the low-
est SCr measurement during hospitalization was used as
the baseline.
AKI etiology
We manually reviewed the electronic medical record
(EMR) of 100 randomly-selected patients and recorded
the AKI etiology where it was known or suspected. In
cases where AKI etiology was suspected to be multi-
factorial, we recorded the two etiologies judged to be of
primary importance.
Diagnostic tests
The following urine, blood, radiology, and pathology
tests were included as AKI diagnostic tests: urine tests –
urinalysis, sediment, sodium, creatinine, urea, eosino-
phils, total protein, and protein electrophoresis (UPEP);
blood tests – anti-neutrophil cytoplasmic antibody
(ANCA), anti-glomerular basement membrane (anti-
GBM) antibody, cryoglobulins, complement component
3 (C3), complement component 4 (C4), free light chains,
and protein electrophoresis (SPEP); radiology tests –
renal ultrasound and computerized tomography of the
abdomen/pelvis (CTAP); pathology test – renal biopsy.
Urine and blood test results were determined to be
normal or abnormal based on reference ranges provided
by the BWH central laboratory. However, some tests
such as urine sodium have normal physiologic variation
and thus reference ranges are not applicable. These tests
were therefore not categorized as normal or abnormal.
Radiographic analysis
We manually reviewed all radiology reports. We consid-
ered CTAP tests as an AKI diagnostic test only if the indi-
cation for the test specifically mentioned AKI, acute renal
failure, elevated SCr, decreased urine output, or concern
for hydronephrosis. We categorized renal ultrasound and
CTAP tests as abnormal if any abnormality was docu-
mented except simple cysts and non-obstructing stones
and masses noted on prior imaging and found to be stable
in size.
Diagnostic yield of abnormal tests
We evaluated the diagnostic yield of one urine test (eosin-
ophils), four blood tests (SPEP, free light chains, ANCA,
and cryoglobulins), and two radiology tests (renal ultra-
sound and CTAP). To evaluate diagnostic yield of urine
and blood tests, we manually reviewed the EMR of pa-
tients with abnormal test results to determine whether the
test affected the patient’s AKI diagnosis or management
during that hospitalization or within 30 days of dis-
charge. For example, for patients with an abnormal
SPEP or serum free light chain test result we deter-
mined from progress notes and discharge summaries
whether they were subsequently diagnosed with a
plasma cell dyscrasia likely to be contributing to their
AKI (e.g., cast nephropathy) or whether the test af-
fected their subsequent management (e.g., intravenous
fluids, chemotherapy, or additional testing such as renal
biopsy or bone marrow biopsy). Additional examples
are provided in Table 1. Since radiology tests often re-
veal abnormal findings that appear chronic or otherwise
have limited immediate clinical relevance, we assessed
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the diagnostic yield of radiology tests based on whether
an abnormal test resulted in a subsequent procedural
intervention. For renal ultrasonography, abnormalities
other than hydronephrosis (e.g., atrophy, cortical thin-
ning, and other chronic changes) were not included in
this analysis, since interventions are not typically per-
formed for these findings.
Sensitivity analysis #1
Some diagnostic tests commonly ordered for the work-
up of glomerulonephritis (ANCA, anti-GBM, and com-
plement levels) and paraproteinemias (SPEP, UPEP, and
serum free light chains) may also be ordered for pur-
poses unrelated to AKI. We therefore manually reviewed
the EMR of 50 randomly-selected patients who were
tested for one of the above glomerulonephritis labs and
50 randomly-selected patients who were tested for one
of the above paraproteinemia labs, and we determined
the approximate frequency with which these tests were
obtained for purposes related or unrelated to AKI. We
classified each test into one of three categories: 1) ob-
tained for AKI evaluation; 2) not obtained for AKI evalu-
ation; 3) unable to determine whether ordered for AKI
evaluation.
Sensitivity analysis #2
To evaluate the appropriateness of testing for glomer-
ulonephritis and paraproteinemias in AKI, we manually
reviewed the EMR of the same 100 patients above. We
developed criteria to evaluate appropriateness of testing
(Table 2) and applied those criteria to each patient.
Further, we evaluated whether appropriateness of test-
ing differed based on patient location (floor vs. ICU),
ordering team (primary team vs. renal consult), and
AKI stage.
Sensitivity analysis #3
Evaluation of diagnostic yield (described above) focused
on the utility of abnormal tests only. We therefore
manually reviewed the EMR of the same 100 patients
above to determine the diagnostic yield of normal test
results. Specifically, we determined the number of nor-
mal or negative tests that affected the patient’s AKI
diagnosis or management during that hospitalization or
within 30 days of discharge. Examples of how a normal
test result could have influenced a patient’s manage-
ment include: continuing with supportive care (e.g.
intravenous fluids for pre-renal azotemia); performing
or deferring a renal biopsy; and starting or discontinu-
ing immunosuppressive medications or plasmapheresis.
Statistical methods
Most of the data shown are descriptive. Continuous data
are shown as median (interquartile range [IQR]). Fisher’s
exact test was used to compare the frequency of appropri-
ate testing based on patient location, ordering team, and




The study cohort included 4903 patients with 5731 epi-
sodes of AKI (70.8 % of which were stage 1, 17.1 % stage
2, and 12.1 % stage 3). The number of patients admitted
1, 2, or ≥ 3 times with AKI was 4323 (75 %), 471 (8 %),
and 109 (2 %), respectively. Additional baseline charac-
teristics are shown in Table 3.
The major etiologies of AKI determined in a random
subset of 100 AKI episodes were ischemic acute tubular
necrosis (24 %), pre-renal azotemia (21 %), nephrotoxic
acute tubular necrosis (10 %), cardiorenal syndrome
(8 %), glomerulonephritis (5 %), obstruction (3 %), and
hepatorenal syndrome (2 %). AKI etiology was unknown
in 22 % of episodes. Etiologies for the remaining 5 % in-
cluded acute interstitial nephritis (AIN), rhabdomyolysis,
and tumor lysis syndrome.
The most commonly ordered tests in AKI were urin-
alysis and automated urine sediment examination
(Fig. 1). Blood tests for vasculitis, glomerulonephritis,
Table 1 Examples of abnormal test results affecting AKI
diagnosis or management
Abnormal Test Examples of Affecting AKI Diagnosis or Management
Urine and Blood Tests
U Eos • Subsequent diagnosis of acute interstitial nephritis
• Renal biopsy to evaluate for interstitial nephritis
• Withdrawal of offending medication for interstitial
nephritis
• Treatment with glucocorticoids
SPEP and SFLCs • Subsequent diagnosis of multiple myeloma,
Waldenstrom’s Macroglobulinemia, or other
paraprotein-related disorder involving the kidneys
• Additional testing such as renal biopsy, bone
marrow biopsy, or skeletal survey
• Treatment with intravenous fluids, glucocorticoids,
or chemotherapy
ANCA • Subsequent diagnosis of ANCA vasculitis involving
the kidneys
• Additional testing such as renal biopsy or skin biopsy
• Treatment with glucocorticoids, cyclophosphamide,
rituximab, or plasmapheresis
Cryo • Subsequent diagnosis of cryoglobulinemia involving
the kidneys
• Additional testing such as renal biopsy






• Placement of a foley catheter
• Placement of a percutaneous nephrostomy tube
• Ureteral stone removal• Ureteral stent placement
Abbreviations: U Eos urinary eosinophils, SPEP serum protein electrophoresis,
SFLCs serum free light chains, ANCA anti-neutrophil cytoplasmic antibody, Cryo
cryoglobulins, CTAP computerized tomography of the abdomen and pelvis
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and paraproteinemias were ordered in fewer than 10 %
overall, and more frequently for higher stages of AKI. Radi-
ology testing with renal ultrasonography or CTAP was ob-
tained in 10 % and 1 %, respectively. Kidney biopsies were
performed in 28 patients (0.5 % of all AKI episodes).
Diagnostic yield of selected tests
Not all diagnostic tests during the course of AKI are ob-
tained specifically for clarification of the cause or treat-
ment of AKI (e.g., automated urinalysis, urine sodium,
urine total protein). We therefore focused on those tests
Table 2 Criteria for determining appropriateness of glomerulonephritis and paraprotein testing in AKI
Glomerulonephritis/vasculitis (≥1 major category to be considered appropriate) Paraprotein disease (≥ 1 major category to be considered appropriate)
A. Hematuria and/or Proteinuria (any of the following):
• RBCs on urine microscopy >25 cells/hpf a
• RBC cast(s) on urine sediment evaluation
• ≥ 3+ proteinuria on urine dipstick or≥ 1 g by quantification
B. Extra-renal manifestation (any of the following):
• Cutaneous lesions (livedo reticularis or purpura)
• Ear, nose, or throat manifestations such as sinusitis, epistaxis, or
nasal ulcers
• Pulmonary disease including hemoptysis or CXR showing patchy
or diffuse opacities and with absence of an alternative etiology
(e.g. pneumonia)
• Arthritis
C. Rapidly progressive AKI
• Increase in serum Cr >100 % in less than 24 h, and absence of an
alternative etiology
D. Known history of glomerulonephritis or vasculitis
A. Proteinuria
• ≥ 3+ on urine dipstick or ≥ 1 g by quantification
B. Known history of a plasma cell dyscrasia (including any of
the following):




• Serum free light chain ratio≥ 100b
C. Hypercalcemia of unknown etiology
• > 11 mg/dlb
D. Anemia of unknown etiology
• Hemoglobin < 10 g/dlbE. Bone lesions
• One or more osteolytic lesions on skeletal radiography, CT,
or PET-CTb
aNot including RBCs due to foley trauma. bAdapted from [17]
Table 3 Baseline characteristics
Variable All AKI Stages (N=5731) Stage 1 (N=4058) Stage 2 (N=981) Stage 3 (N=692)
Age (yr) – median (IQR) 64 (52–75) 64 (53–75) 62 (52–72) 64 (52–74)
Female sex (%) 49.6 49.7 54.1 42.6
Race (%)
White 83.0 82.9 84.3 81.9
Black 8.9 8.7 8.4 10.7
Hispanic 5.3 5.6 4.6 4.7
Other 2.7 2.8 2.7 2.7
Comorbidities (%)
Malignancy 28.6 30.1 27.0 21.7
Hypertension 26.3 29.4 22.8 13.3
Diabetes Mellitus 18.6 20.1 16.0 13.6
Congestive Heart Failure 18.1 19.4 15.2 15.0
Chronic Pulmonary Disease 13.2 14.6 11.8 7.2
Chronic Kidney Disease 11.2 11.4 6.6 16.6
Chronic Liver Disease 4.5 3.9 4.8 7.7
Laboratory values on admission – median (IQR)
Serum creatinine, mg/dL 1.0 (0.8-1.5) 1.0 (0.7-1.3) 1.1 (0.8-1.5) 1.9 (1.0-3.6)
Hemoglobin, g/dL 11.1 (9.7-12.7) 11.2 (9.9-12.7) 11.1 (9.7-12.8) 10.3 (8.9-11.8)
WBCs, 1000/μL 8.9 (6.3-12.8) 8.7 (6.3-12.4) 9.6 (6.5-14.1) 9.3 (5.9-14.3)
Albumin, g/dL 3.5 (3.0-3.9) 3.6 (3.1-4.0) 3.4 (2.9-3.9) 3.2 (2.8-3.7)
Stages 1, 2, and 3 refer to AKI severity according to the criteria established by the Kidney Disease Improving Global Outcomes (KDIGO) Work Group [12] as follows:
stage 1, increase in serum creatinine 1.5 to 1.9 times baseline or absolute increase ≥0.3 mg/dl; stage 2, increase in serum creatinine 2.0 to 2.9 times baseline; stage 3,
increase in serum creatinine ≥3.0 times baseline, or increase ≥0.5 mg/dl to an absolute level ≥4.0 mg/dl, or initiation of renal replacement therapy
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used most commonly to diagnose specific causes of AKI
such as interstitial nephritis, paraprotein-related kidney
disease, glomerulonephritides, and obstructive uropathy.
Data on the number of tests performed, the number that
were abnormal, and the number that affected AKI diag-
nosis or management are shown in Fig. 2. Additional
data on frequency of abnormal results by AKI stage are
shown in Table 4.
Urine eosinophils
Urine eosinophil testing was obtained in 7 % of AKI epi-
sodes (3 %, 9 %, and 24 % in patients with AKI stages 1, 2,
and 3, respectively). Abnormal results (urine eosinophils ≥
1 %) were found in 7 % of tests. Among the abnormal re-
sults, 24 % were in stage 1, 24 % were in stage 2, and 52 %
were in stage 3. The median urine eosinophil % among
those with abnormal results was 2 (IQR, 1-3). Among
A.  Urine Tests
B.  Plasma Tests


























Fig. 1 Frequency of diagnostic testing in AKI for A) urine tests, B) plasma tests, and C) radiology/pathology tests.. Frequency (%) is given for obtaining
each diagnostic test at least once per episode of AKI. Abbreviations: UA, urinalysis; UPEP, urine protein electrophoresis; ANCA, anti-neutrophil cyto-
plasmic antibody; GBM, glomerular basement membrane; Cryo, cryoglobulins; C3, complement component 3; C4, complement component 4;
FLCs, free light chains; SPEP, serum protein electrophoresis; CTAP, computerized tomography of the abdomen and pelvis
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those with abnormal results, the presumptive diagnosis
was AIN in 28 %. Kidney biopsy was performed in two pa-
tients with eosinophiluria and showed AIN in one, and
vasculitis in the other.
SPEP
SPEP was ordered in 6 % of all AKI episodes and was
abnormal in 19 %. Among AKI episodes with an abnor-
mal SPEP, 75 % were IgG, 12 % were IgA, 8 % were IgM,
and in 5 % only faint free light chains were identified;
overall, 63 % consisted of monoclonal kappa and 37 %
consisted of monoclonal lambda; the median M-spike
concentration was 0.9 (IQR, 0.5-2.4 g/dl). In only 9 cases
(2.6 % of the tests) did a positive SPEP affect AKI diag-
nosis or management (Fig. 2).
ANCA and anti-GBM
ANCA testing was ordered in 3 % of AKI episodes. Ab-
normal results were found in 11 % of tests, with median
titers of 1:20 (IQR, 1:20 to 1:180). Among the abnormal
results, 80 % were positive for p-ANCA and 20 % for
c-ANCA. In only 5 cases (3 % of the tests) did a positive
ANCA affect diagnosis or management (Fig. 2). In 3 of
































#Tests 419 / 29 / 7 340 / 65 / 9 89 / 37 / 4 189 / 20 / 5 78 / 17 / 2
% of Total --- / 6.9 / 1.7 --- / 19.1 / 2.6 --- / 41.6 / 4.5 --- / 10.6 / 2.6 --- / 21.8 / 2.6
#Tests 567 /  109  /   35 54  /  18  /   11
% of Total ---- /  19.2 /   6.2 ---- /   33.3 / 20.4
Fig. 2 Diagnostic Yield. (a) Diagnostic yield was evaluated for blood and urine tests based on the number of abnormal tests that affected AKI
diagnosis or management. (b) Diagnostic yield was evaluated for radiology tests based on the number of abnormal tests that resulted in a
procedural intervention. For renal ultrasonography, abnormalities other than hydronephrosis (e.g. atrophy, cortical thinning, and other chronic
changes) were not included in this analysis, since interventions are not typically performed for these findings. Abbreviations: U Eos, urinary
eosinophils; SPEP, serum protein electrophoresis; FLCs, serum free light chains; ANCA, anti-neutrophil cytoplasmic antibody; Cryo, cryoglobulins;
CTAP, computerized tomography of the abdomen and pelvis
Leaf et al. BMC Nephrology  (2016) 17:9 Page 6 of 10
was confirmed by renal biopsy; in the remaining 2 cases, a
presumptive diagnosis of ANCA vasculitis was made clin-
ically. Anti-GBM antibodies were tested in 1 % of AKI epi-
sodes and were negative in all.
Radiology testing
Renal ultrasound was ordered in 567 (10 %) of AKI epi-
sodes. Abnormal results were detected in 196 (35 %) of
the tests. Severe abnormalities such as severe or bilateral
hydronephrosis were less frequently found (2 % and 10 %,
respectively; Table 5). Hydronephrosis was detected in 109
(19 %) of the tests, among which 35 (32 %) resulted in a
procedural intervention (Fig. 2). Among the 35 cases of
that resulted in an intervention, a clinical history of meta-
static or genitourinary cancer (N = 26), hemorrhagic cyst-
itis (N = 2), and other comorbidities raising suspicion for
obstruction were present in each case.
CTAP testing was ordered in 0.9 % of AKI episodes.
Abnormal results were detected in 18 out of 54 (33 %)
tests. Among the abnormal tests, 61 % resulted in an
intervention (Fig. 2). CTAP, but not renal ultrasonography,
was more likely to be abnormal among patients with
higher AKI stages (Table 4). In general, the frequency of
detecting abnormalities was greater with radiology tests
than with urine or blood tests.
Renal biopsy
Renal biopsies were obtained in 28 patients (AKI stage 1
[N = 10], stage 2 [N = 2], and stage 3 [N = 16]). The diag-
noses were immune-complex glomerulonephritis (22 %),
diabetic kidney disease (14 %), pauci-immune crescentic
glomerulonephritis (14 %), AIN (14 %), acute tubular in-
jury (7 %), focal segmental glomerulosclerosis (7 %), and
other miscellaneous diagnoses of lower incidence (N = 1
each, or 3.6 %): thrombotic microangiopathy, minimal
change disease, membranous glomerulopathy, lupus
nephritis, advanced chronic changes, and chronic tubu-
lointerstitial nephritis.
Sensitivity analyses
We conducted the following sensitivity analyses among
50 randomly selected patients who were tested for one
of the “glomerulonephritis” labs (ANCA, anti-GBM, or
complements), and an additional 50 randomly selected
patients who were tested for one of the “paraproteine-
mia” labs (SPEP, UPEP, and serum free light chains):
Sensitivity analysis #1 – frequency of testing related or
unrelated to AKI
Among the patients who were tested for one of the
glomerulonephritis labs, 46 % were ordered specifically
for AKI, 12 % were ordered for reasons unrelated to
AKI, and 42 % were ordered for reasons which were not
clearly documented. Among the 50 patients who were
tested for one of the paraproteinemia labs, 44 % were or-
dered specifically for AKI, 6 % were ordered for reasons
unrelated to AKI, and 50 % were ordered for reasons
which were not clearly documented.
Table 4 Frequency of abnormal results
Test Cutoff for “abnormal” All Stages (N = 5731) Stage 1 (N = 4058) Stage 2 (N = 981) Stage 3 (N = 692)
Urine Tests
Eosinophils ≥1 % 6.9 5.8 7.2 7.5
Total Protein >15 mg/dl 70.8 63.0 64.3 83.3
UPEP M spike 7.9 5.0 9.8 10.0
Blood Tests
ANCA Titer > 1:20 10.6 8.0 3.7 14.9
Anti-GBM ≥1.0 0 0 0 0
Cryoglobulin >0 % 21.8 26.3 0 21.2
C3 <90 mg/dl 36.5 26.9 21.1 45.6
C4 <10 mg/dl 12.9 11.6 10.5 14.3
Free Light Chains See below 41.6 44.7 42.9 36.7
SPEP M spike 19.1 16.4 23.9 19.7
Radiology Tests
Renal Ultrasound See Methods 34.6 40.6 23.4 34.9
CT Abdomen/Pelvis See Methods 33.3 26.7 27.3 39.3
Frequency (%) of abnormal results was calculated by dividing the #tests ordered by the #abnormal results, multiplied by 100. Urinary tests with normal
physiologic variation (e.g. sodium) were not included since there is no defined cutoff for “abnormal.” Similarly, renal biopsy was not included. Serum free light
chains were considered abnormal if the Kappa/Lambda ratio was <0.26 or >1.65. Abbreviations: UPEP, urine protein electrophoresis; ANCA, anti-neutrophil cytoplasmic
antibody; GBM, glomerular basement membrane; C3, complement component 3; C4, complement component 4; SPEP, serum protein electrophoresis
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Sensitivity analysis #2 – appropriateness of testing
Using prespecified criteria (Table 2), we determined ap-
propriateness of glomerulonephritis and paraproteine-
mia testing in AKI. Overall, glomerulonephritis and
paraproteinemia testing was appropriate in 50 % and
54 % of tests, respectively (Fig. 3). When testing was
ordered by the renal consult team compared to the
primary team, appropriateness of testing was higher for
glomerulonephritis testing (P=0.047), and showed a
similar trend that did not reach statistical significance
for paraproteinemia testing (P=0.09, Fig. 3). Similarly,
when testing was ordered in patients with higher AKI
stages, we found that appropriateness of testing was
higher for paraproteinemia testing (P=0.04) but not for
glomerulonephritis testing (P=0.13, Fig. 3).
Sensitivity analysis #3 – diagnostic yield of normal tests
Among the patients who underwent one of the glomer-
ulonephritis tests, testing was normal in 45 out of 50
(90 %) tests, and affected AKI diagnosis or management
in only 1 out of the 45 (2.2 %) normal tests (and in 0 out
of the 5 abnormal tests). Specifically, in one case a negative
ANCA test resulted in discontinuation of immunosuppres-
sive medications. Among the patients who underwent one
of the paraproteinemia tests, testing was normal in 39 out
of 50 (78 %) tests, and affected AKI diagnosis or manage-
ment in 0 out of the 39 normal tests (and in 4 out of the
11 abnormal tests).
Discussion
In this retrospective study we characterized the patterns
and clinical utility of a wide variety of AKI diagnostic
tests, including urine, blood, radiology, and pathology
tests. Our key findings are: 1) frequency of testing in-
creases with higher AKI stage for nearly all diagnostic
tests; 2) frequency of abnormal results increases with
higher AKI stage for some, but not all, diagnostic tests;
and 3) many of the tests evaluated have low clinical util-
ity. In particular, selected urine and blood tests are
unlikely to impact AKI diagnosis or management. Cu-
mulatively, these data suggest a paucity of actionable
diagnostic tests in AKI.
Previous studies have examined the utility of a limited
number of AKI diagnostic tests in isolation, including
urine microscopy [11], urine eosinophils [14], the frac-
tional excretion of sodium [15] and urea [16], and renal
ultrasonography [10]. Most of these studies have focused
on a single diagnostic test, have been limited by modest
sample sizes, and have focused on test performance
without inclusion of data on frequency of testing. None,
to our knowledge, have simultaneously evaluated the
patterns and test performance of a wide variety of AKI
diagnostic tests in a large AKI cohort.
To assess diagnostic yield, we focused mostly on abnor-
mal test results. Although normal test results can also be
clinically useful by ruling out diagnoses, our sensitivity
analysis of normal test results for glomerulonephritis and
paraproteinemia labs revealed very low diagnostic yield.
We therefore focused on abnormal test results, and evalu-
ated diagnostic yield based on whether the result influ-
enced AKI diagnosis or management. We found selected
tests (e.g. urine eosinophils) are unlikely to be clinically
useful in AKI. In contrast, renal ultrasonography and
CTAP were much more likely to be useful, especially
when the clinical history was suggestive. This was best ex-
emplified by renal ultrasonography: among the cases of
hydronephrosis that were detected and intervened upon,
100 % had a clinical history raising suspicion for obstruc-
tion. Thus, diagnostic testing should be based on both
pre-test probability from the clinical context as well as an
appreciation of the diagnostic value and actionability of
the data provided by the test.
Among the urine, blood, and radiology tests examined
in Fig. 2, the ratio of the number of tests ordered to the
number of tests that had clinical utility – a concept similar
to number needed to screen (NNS) – ranged substantially:
from 5 in the case of CTAP to 60 in the case of urine eo-
sinophils. In general the ratio was much higher for urine
Table 5 Renal ultrasound abnormalities
All Stages (N = 567) Stage 1 (N = 187) Stage 2 (N = 111) Stage 3 (N = 269)
Any abnormality – no. (%) 196 (35) 76 (41) 26 (23) 94 (35)
Hydronephrosis – no. (%) 109 (19) 37 (20) 20 (18) 52 (19)
Mild – no. (%) 63 (11) 24 (13) 12 (11) 27 (10)
Moderate – no. (%) 33 (6) 10 (5) 5 (5) 18 (7)
Severe – no. (%) 13 (2) 3 (2) 3 (3) 7 (3)
Unilateral – no. (%) 52 (9) 24 (13) 11 (10) 17 (6)
Bilateral – no. (%) 57 (10) 13 (7) 9 (8) 35 (13)
Increased echogenicity – no. (%) 70 (12) 28 (15) 5 (5) 37 (18)
Cortical thinning – no. (%) 27 (5) 18 (10) 3 (3) 6 (2)
Atrophy – no. (%) 10 (2) 5 (3) 1 (1) 4 (1)
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and blood tests, suggesting lower diagnostic yield, com-
pared to radiology tests. In the case of renal ultrasonog-
raphy, for example, the 567 tests ordered led to 35
interventions, resulting in a NNS of 16. This is similar to
the NNS observed among high risk patients in a prior
study that evaluated the utility of renal ultrasonography in
AKI [10]. For urine and blood tests, on the other hand, we
would speculate that clinicians may be aware of their poor
predictive value, and therefore base most of their diagnos-
tic and management decisions on other data such as clin-
ical history and physical examination. For example, a
recent study evaluated the utility of urine eosinophils in
the diagnosis of AIN, using renal biopsies as the gold
standard, and found that the presence of urine eosinophils
performed very poorly in distinguishing AIN from other
etiologies of AKI [14]. Abnormal radiology tests, on the
other hand, may provide more actionable data, such as
amelioration of obstruction.
We acknowledge several limitations. Some test re-
sults may have been considered abnormal based on
reference ranges but may have been clinically insignifi-
cant. Other tests may have been ordered for reasons
unrelated to AKI, such as routine urinalysis on admis-
sion, which may have led to overestimation of the fre-
quency of AKI diagnostic testing. We attempted to
minimize this bias by focusing on tests which are most
commonly ordered for the diagnostic evaluation of
AKI and not for other purposes. In the case of CTAP,
testing was only included if ordered specifically for
AKI. We also performed sensitivity analyses on tests
for glomerulonephritis and paraproteinemias to deter-
mine the fraction of tests that were ordered for reasons
unrelated to AKI. We found that only a minority of
tests were ordered for reasons unrelated to AKI,
though a large portion were also ordered for reasons






























































Fig. 3 Appropriateness of diagnostic testing in AKI for A) glomerulonephritis and B) paraprotein testing
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Due to institutional restrictions we were unable to show
data on the cost of diagnostic testing. An additional limi-
tation is that because this was a single-center study the
findings may not be generalizable to other settings; how-
ever, this limitation may be at least partially offset by the
large sample size and heterogeneous nature of our patient
population. Finally, we were unable to evaluate the diag-
nostic yield of AKI testing in selected subgroups, such as
patient location (general medical floor versus ICU), order-
ing team (primary team versus renal consult), or AKI
severity. However, we conducted sensitivity analyses to
evaluate whether appropriateness of diagnostic testing var-
ied based on these factors. Although we found that appro-
priateness of testing may increase for some tests when
ordered by the renal consult rather than the primary team,
patients who require renal consultation may have greater
severity of AKI; thus, we cannot exclude the possibility of
confounding, and therefore this finding should be inter-
preted with caution.
Conclusions
In summary, a large number of diagnostic tests are
available for the evaluation of AKI, and determining
which test to order should be based on estimates of
pre-test probability and performance characteristics of
the test. Our data suggest that many of the currently
available tests have limited clinical utility, even when
they are abnormal or “positive”. Thus, developing better
diagnostic tests that provide reliable and actionable
data on AKI diagnosis or management should be a pri-
ority in AKI research. The dearth of such tests may be
a key reason why therapeutic advances to improve out-
comes in AKI have been largely unsuccessful.
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